PT2438087T - Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório - Google Patents
Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratórioInfo
- Publication number
- PT2438087T PT2438087T PT107244972T PT10724497T PT2438087T PT 2438087 T PT2438087 T PT 2438087T PT 107244972 T PT107244972 T PT 107244972T PT 10724497 T PT10724497 T PT 10724497T PT 2438087 T PT2438087 T PT 2438087T
- Authority
- PT
- Portugal
- Prior art keywords
- hrsv
- prevention
- treatment
- syncytial virus
- tract infections
- Prior art date
Links
- 241000711920 Human orthopneumovirus Species 0.000 title 1
- 206010057190 Respiratory tract infections Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18439609P | 2009-06-05 | 2009-06-05 | |
US26501409P | 2009-11-30 | 2009-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2438087T true PT2438087T (pt) | 2017-08-04 |
Family
ID=42333502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT107244972T PT2438087T (pt) | 2009-06-05 | 2010-06-07 | Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório |
Country Status (25)
Country | Link |
---|---|
US (3) | US8945567B2 (pt) |
EP (2) | EP3205670A1 (pt) |
JP (2) | JP6081196B2 (pt) |
KR (1) | KR101852204B1 (pt) |
CN (2) | CN105061592A (pt) |
AU (1) | AU2010255638B2 (pt) |
BR (1) | BRPI1010830A2 (pt) |
CA (1) | CA2764398A1 (pt) |
CY (1) | CY1119265T1 (pt) |
DK (1) | DK2438087T3 (pt) |
ES (1) | ES2643034T3 (pt) |
HR (1) | HRP20171194T1 (pt) |
HU (1) | HUE035773T2 (pt) |
IL (1) | IL216341A0 (pt) |
LT (1) | LT2438087T (pt) |
MX (1) | MX340541B (pt) |
NZ (1) | NZ597314A (pt) |
PH (1) | PH12019500644A1 (pt) |
PL (1) | PL2438087T3 (pt) |
PT (1) | PT2438087T (pt) |
RU (2) | RU2577134C2 (pt) |
SG (1) | SG176095A1 (pt) |
SI (1) | SI2438087T1 (pt) |
WO (1) | WO2010139808A2 (pt) |
ZA (1) | ZA201108892B (pt) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009254501B2 (en) | 2008-06-05 | 2014-07-31 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
MX340541B (es) | 2009-06-05 | 2016-07-13 | Alblynx Nv | Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio. |
EP2507262A1 (en) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
US8962807B2 (en) | 2009-12-14 | 2015-02-24 | Ablynx N.V. | Single variable domain antibodies against OX40L, constructs and therapeutic use |
EP2533761B1 (en) | 2010-02-11 | 2019-03-27 | Ablynx N.V. | Methods and compositions for the preparation of aerosols |
WO2012056000A1 (en) | 2010-10-29 | 2012-05-03 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
EP3590950A1 (en) | 2011-05-09 | 2020-01-08 | Ablynx NV | Method for the production of immunoglobulin single varible domains |
US11339208B1 (en) | 2012-05-31 | 2022-05-24 | United States Of America As Represented By The Secretary Of The Air Force | Camelidae single-domain antibodies against Yersinia pestis and methods of use |
PL2968520T3 (pl) | 2013-03-14 | 2022-01-03 | Macrogenics, Inc. | Dwuspecyficzne cząsteczki, które są immunoreaktywne wobec immunologicznych komórek efektorowych wykazujących ekspresję receptora aktywującego |
CN105636936B (zh) | 2013-08-21 | 2022-04-05 | 詹森生物制药有限公司 | 抗病毒化合物 |
SG11201700851WA (en) * | 2014-08-05 | 2017-03-30 | Alios Biopharma Inc | Combination therapy for treating a paramyxovirus |
CA2963991A1 (en) | 2014-09-29 | 2016-04-07 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
SG11201702688UA (en) * | 2014-10-10 | 2017-04-27 | Ablynx Nv | Methods of treating rsv infections |
HUE044199T2 (hu) | 2014-10-10 | 2019-10-28 | Ablynx Nv | Inhalációs készülék légúti betegségek aeroszolos terápiájában való alkalmazásra |
MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
EP3313432A1 (en) * | 2015-06-18 | 2018-05-02 | VIB vzw | Immunoglobulin single variable domain antibody against rsv prefusion f protein |
EP3124042A1 (en) * | 2015-07-28 | 2017-02-01 | VIB, vzw | Immunoglobulin single variable domain antibody against rsv prefusion f protein |
CN109311968A (zh) | 2016-05-02 | 2019-02-05 | 埃博灵克斯股份有限公司 | 治疗rsv感染 |
WO2017220645A1 (en) | 2016-06-23 | 2017-12-28 | Ablynx N.V. | Improved pharmacokinetic assays for immunoglobulin single variable domains |
CN106279410B (zh) * | 2016-09-29 | 2019-08-20 | 华南理工大学 | 一种二型登革热病毒ns1蛋白多价纳米抗体及制备方法 |
US11479600B2 (en) | 2016-10-21 | 2022-10-25 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
AU2017345786B2 (en) | 2016-10-21 | 2024-08-01 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
BR112019008063A2 (pt) | 2016-10-21 | 2019-07-02 | Adimab Llc | anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso |
WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
US11725045B2 (en) | 2017-10-13 | 2023-08-15 | Mapp Biopharmaceutical, Inc. | Anti-respiratory syncytial virus antibodies, methods of their generation and use |
JP7123607B2 (ja) * | 2018-04-09 | 2022-08-23 | シャープ株式会社 | ユーザ装置、制御装置、及び通信制御方法 |
KR20210150509A (ko) | 2019-04-10 | 2021-12-10 | 리제너론 파마슈티칼스 인코포레이티드 | Ret에 결합하는 인간 항체 및 그것의 사용 방법 |
CN111748571B (zh) * | 2019-10-11 | 2022-05-03 | 浙江禾霖生物科技有限公司 | 一种将枯草芽孢杆菌工程化为生产纳米抗体的多功能稳定平台的方法 |
IL293282A (en) | 2019-11-25 | 2022-07-01 | Mabloc Llc | Yellow fever antiviral antibodies and methods of making and using them |
US20210230248A1 (en) * | 2020-01-25 | 2021-07-29 | Jun Chen | Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof |
WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
CN116693673B (zh) * | 2023-07-26 | 2023-10-20 | 中国人民解放军军事科学院军事医学研究院 | 广谱抗SARS和SARS-CoV-2的纳米抗体、多价纳米抗体及其应用 |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1120945A (en) | 1964-08-11 | 1968-07-24 | Fisons Pharmaceuticals Ltd | Applicator in combination with a pressurised aerosol dispensing container |
WO1990004788A1 (en) | 1988-10-28 | 1990-05-03 | Genentech, Inc. | Method for identifying active domains and amino acid residues in polypeptides and hormone variants |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1991015581A1 (en) | 1990-04-05 | 1991-10-17 | Roberto Crea | Walk-through mutagenesis |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
CA2137558A1 (en) | 1992-07-17 | 1994-02-03 | Wayne A. Marasco | Method of intracellular binding of target molecules |
WO1994004678A1 (en) | 1992-08-21 | 1994-03-03 | Casterman Cecile | Immunoglobulins devoid of light chains |
DE69434447T2 (de) | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | Für die gentherapie verwendbare plasmide |
ATE198490T1 (de) | 1993-06-09 | 2001-01-15 | Unilever Nv | Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen |
US6091639A (en) | 1993-08-27 | 2000-07-18 | Kabushiki Kaisha Toshiba | Non-volatile semiconductor memory device and data programming method |
ATE400651T1 (de) | 1993-09-10 | 2008-07-15 | Univ Columbia | Verwendung von grünem fluoreszenzprotein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
JPH10501681A (ja) | 1994-02-22 | 1998-02-17 | ダナ−ファーバー キャンサー インスティチュート | 核酸送達システムならびにその合成および使用方法 |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5693492A (en) | 1995-05-05 | 1997-12-02 | Merck & Co., Inc. | DNA encoding glutamate gated chloride channels |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
EP0851874B1 (en) | 1995-09-22 | 1999-09-15 | Novo Nordisk A/S | Novel variants of green fluorescent protein, gfp |
US6027881A (en) | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
US6020182A (en) * | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
CA2270288A1 (en) * | 1996-11-01 | 1998-05-14 | Smithkline Beecham Corporation | Human monoclonal antibodies |
WO1998021355A1 (en) | 1996-11-15 | 1998-05-22 | Life Technologies, Inc. | Mutants of green fluorescent protein |
WO1998022141A2 (en) | 1996-11-19 | 1998-05-28 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
FR2766826B1 (fr) | 1997-08-04 | 2001-05-18 | Pasteur Institut | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules |
EP1469883A2 (en) | 1998-02-19 | 2004-10-27 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
AU779162B2 (en) | 1999-02-05 | 2005-01-06 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
OA11862A (en) | 1999-04-22 | 2006-03-02 | Unilever Nv | Inhibition of viral infection using monovalent antigen-binding proteins. |
CO5280147A1 (es) | 1999-05-18 | 2003-05-30 | Smithkline Beecham Corp | Anticuerpo humano monoclonal |
IL147920A0 (en) | 1999-08-02 | 2002-08-14 | Keygene Nv | Method for generating cgmmv resistant plants, genetic constructs, and the obtained cgmmv-resistant plants |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
PT1240337E (pt) | 1999-12-24 | 2007-01-31 | Genentech Inc | Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos |
US6741957B1 (en) | 2000-07-21 | 2004-05-25 | Daimlerchrysler Corporation | Analytical tire model for vehicle durability and ride comfort analysis |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
US7054297B1 (en) | 2000-12-28 | 2006-05-30 | Cisco Technology, Inc. | Distribution of packets to high data rate communications devices using multicast protocols |
CA2433877C (en) | 2001-01-17 | 2014-11-18 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
EP1377306A1 (en) | 2001-03-09 | 2004-01-07 | Dyax Corp. | Serum albumin binding moieties |
DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
AU2002355477B2 (en) | 2001-08-03 | 2008-09-25 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
FR2829940A1 (fr) | 2001-09-27 | 2003-03-28 | Synt Em | Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central |
KR100599789B1 (ko) | 2001-12-03 | 2006-07-12 | 삼성에스디아이 주식회사 | 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법 |
WO2003050531A2 (en) | 2001-12-11 | 2003-06-19 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
JP2005516939A (ja) | 2001-12-18 | 2005-06-09 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 診断及び治療用途の精製c型肝炎ウイルス外被タンパク質 |
KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
BRPI0315666B8 (pt) | 2002-10-23 | 2021-05-25 | Ludwig Inst For Cancer Res Ltd | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos |
BRPI0316092B8 (pt) | 2002-11-08 | 2021-05-25 | Ablynx Nv | anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos |
EP2336179A1 (en) | 2002-11-08 | 2011-06-22 | Ablynx N.V. | Stabilized single domain antibodies |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
EP1578842B1 (en) | 2002-12-31 | 2009-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
EP2390270A1 (en) | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
EP2395016A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
US7070786B2 (en) | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
US20050136428A1 (en) | 2003-06-27 | 2005-06-23 | Roberto Crea | Look-through mutagenesis |
PT1639011E (pt) | 2003-06-30 | 2009-01-20 | Domantis Ltd | Anticorpos (dab) de domínio único peguilados |
WO2005001690A2 (de) | 2003-06-30 | 2005-01-06 | Siemens Aktiengesellschaft | Verfahren zur überwachung des programmlaufs in einem mikro-computer |
AU2003264053A1 (en) | 2003-08-12 | 2005-03-10 | William M. Yarbrough | Treatment for acne vulgaris and method of use |
EP1512696A1 (en) | 2003-08-14 | 2005-03-09 | Diatos | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
DK1737971T3 (da) | 2004-01-20 | 2017-11-13 | Merus Nv | Blandinger af bindingsproteiner |
US20050288491A1 (en) | 2004-02-17 | 2005-12-29 | Wilson David S | Super-humanized antibodies against respiratory syncytial virus |
US7207410B2 (en) | 2004-04-29 | 2007-04-24 | Daimlerchrysler Corporation | Apparatus and method for enhanced impact sensing |
KR101699142B1 (ko) | 2004-06-18 | 2017-01-23 | 암브룩스, 인코포레이티드 | 신규 항원-결합 폴리펩티드 및 이의 용도 |
ES2372503T3 (es) | 2004-07-06 | 2012-01-20 | Bioren, Inc. | Mutagénesis revisada para desarrollar polipéptidos alterados con propiedades potenciadas. |
US7180370B2 (en) | 2004-09-01 | 2007-02-20 | Micron Technology, Inc. | CMOS amplifiers with frequency compensating capacitors |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
WO2006034292A2 (en) | 2004-09-21 | 2006-03-30 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
CA2583017A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
TW200636064A (en) * | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
US20060115485A1 (en) | 2004-10-29 | 2006-06-01 | Medimmune, Inc. | Methods of preventing and treating RSV infections and related conditions |
WO2006059108A2 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
JP5011277B2 (ja) | 2005-04-06 | 2012-08-29 | アイビーシー・ファーマシューティカルズ・インコーポレーテッド | ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用 |
AU2006234847A1 (en) | 2005-04-08 | 2006-10-19 | Medimmune, Llc | Antibodies against mammalian metapneumovirus |
MX342271B (es) | 2005-05-18 | 2016-09-21 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
CN101646689A (zh) | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
EP2086998B1 (en) | 2006-10-11 | 2011-12-07 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
AU2007310838A1 (en) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
EP2097449A1 (en) | 2006-12-05 | 2009-09-09 | Ablynx N.V. | Peptides capable of binding to serum proteins |
EP2097451A2 (en) | 2006-12-22 | 2009-09-09 | Ablynx N.V. | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies |
WO2009004065A2 (en) | 2007-07-03 | 2009-01-08 | Ablynx N.V. | Providing improved immunoglobulin sequences by mutating cdr and/or fr positions |
JP2011504740A (ja) | 2007-11-27 | 2011-02-17 | アブリンクス エン.ヴェー. | ヘテロ二量体サイトカイン及び/又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド |
EP2096121A1 (en) | 2008-02-29 | 2009-09-02 | Institut Pasteur Of Shanghai | Antiviral peptides comprising lipid attachment signals and methods of use |
AU2009254501B2 (en) | 2008-06-05 | 2014-07-31 | Ablynx N.V. | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases |
ES2701649T3 (es) | 2009-01-14 | 2019-02-25 | Ablynx Nv | Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos |
PL2424889T3 (pl) | 2009-04-30 | 2016-01-29 | Ablynx Nv | Sposób wytwarzania przeciwciał domenowych |
MX340541B (es) | 2009-06-05 | 2016-07-13 | Alblynx Nv | Secuencias de aminoacidos mejoradas dirigidas contra virus sincitial respiratorio humano y polipeptidos que comprenden las mismas para la prevencion y/o tratamiento de infecciones del tracto respiratorio. |
EP2507262A1 (en) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
-
2010
- 2010-06-07 MX MX2011013013A patent/MX340541B/es active IP Right Grant
- 2010-06-07 CA CA2764398A patent/CA2764398A1/en not_active Abandoned
- 2010-06-07 WO PCT/EP2010/057921 patent/WO2010139808A2/en active Application Filing
- 2010-06-07 JP JP2012513641A patent/JP6081196B2/ja not_active Expired - Fee Related
- 2010-06-07 SG SG2011084274A patent/SG176095A1/en unknown
- 2010-06-07 AU AU2010255638A patent/AU2010255638B2/en not_active Ceased
- 2010-06-07 BR BRPI1010830A patent/BRPI1010830A2/pt not_active IP Right Cessation
- 2010-06-07 ES ES10724497.2T patent/ES2643034T3/es active Active
- 2010-06-07 NZ NZ597314A patent/NZ597314A/xx not_active IP Right Cessation
- 2010-06-07 EP EP17162779.7A patent/EP3205670A1/en not_active Withdrawn
- 2010-06-07 CN CN201510509040.3A patent/CN105061592A/zh active Pending
- 2010-06-07 CN CN201080024764.4A patent/CN102459332B/zh not_active Expired - Fee Related
- 2010-06-07 US US13/375,357 patent/US8945567B2/en active Active
- 2010-06-07 PT PT107244972T patent/PT2438087T/pt unknown
- 2010-06-07 EP EP10724497.2A patent/EP2438087B1/en active Active
- 2010-06-07 PL PL10724497T patent/PL2438087T3/pl unknown
- 2010-06-07 KR KR1020127000199A patent/KR101852204B1/ko active IP Right Grant
- 2010-06-07 SI SI201031523T patent/SI2438087T1/sl unknown
- 2010-06-07 RU RU2011153239/10A patent/RU2577134C2/ru active
- 2010-06-07 LT LTEP10724497.2T patent/LT2438087T/lt unknown
- 2010-06-07 HU HUE10724497A patent/HUE035773T2/en unknown
- 2010-06-07 RU RU2016103067A patent/RU2016103067A/ru unknown
- 2010-06-07 DK DK10724497.2T patent/DK2438087T3/en active
-
2011
- 2011-11-02 ZA ZA2011/08892A patent/ZA201108892B/en unknown
- 2011-11-14 IL IL216341A patent/IL216341A0/en unknown
-
2014
- 2014-09-29 US US14/499,772 patent/US9803001B2/en active Active
-
2017
- 2017-01-18 JP JP2017006690A patent/JP6677659B2/ja not_active Expired - Fee Related
- 2017-08-02 HR HRP20171194TT patent/HRP20171194T1/hr unknown
- 2017-08-08 CY CY20171100847T patent/CY1119265T1/el unknown
- 2017-09-22 US US15/712,247 patent/US11028151B2/en active Active
-
2019
- 2019-03-25 PH PH12019500644A patent/PH12019500644A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT2438087T (lt) | Trivalenčiai nanokūno konstruktai prieš žmogaus respiratorinį sincitinį virusą (hrsv), skirti kvėpavimo takų infekcijų profilaktikai ir (arba) gydymui | |
HK1172350A1 (zh) | 針對人呼吸道合胞病毒 的抗體以及使用方法 | |
HK1199607A1 (en) | Human milk oligosaccharides for preventing injury and or promoting healing of the gastrointestinal tract | |
PL2521562T3 (pl) | Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych | |
HK1196131A1 (zh) | 用於治療或預防呼吸道合胞病毒疾病的化合物 | |
ZA201304638B (en) | Composition for use in the prevention and /or treatment of skin condition and skin diseases. | |
IL227193B (en) | Plant extracts for the treatment and prevention of inflammation | |
EP2349140A4 (en) | DEVICES, SYSTEMS AND METHODS FOR TREATING SLEEP APNEA | |
IL200330A0 (en) | Recombinant antibodies for treatment of respiratory syncytial virus infections | |
GB2496794B (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
ZA201209289B (en) | Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract | |
EP2427061A4 (en) | GALLIUM FORMULATION FOR THE TREATMENT AND PROPHYLAXIS OF INFECTION DISEASES | |
EP2651439A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HUMAN ADENOVIRUS 36 INFECTION | |
IL216967B (en) | The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases | |
GB2496800B (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition | |
EP2521554A4 (en) | SUBSTANCES AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS | |
HK1197058A1 (en) | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | |
EP2222258A4 (en) | SYSTEMS AND METHOD FOR HEAT TREATMENT OF BODY TISSUE | |
EP2361317A4 (en) | USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
PL2895180T3 (pl) | Kompozycja do zapobiegania i leczenia ostrych i nawracających zakażeń dróg moczowych | |
EP2508192A4 (en) | THERAPEUTIC AGENT FOR THE PREVENTION AND TREATMENT OF THE AFFECTIONS OF THE GENITAL AND URINARY SYSTEM IN MAN | |
HK1188565A1 (en) | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | |
EP2160191A4 (en) | SUPPRESSION OF VIRUSES INVOLVED IN A DISEASE OR RESPIRATORY INFECTION | |
SI2315580T1 (sl) | Farmacevtski pripravki in postopki za zdravljenjeinfekcij respiratornega trakta | |
ZA201400442B (en) | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |